Plain-English translation of NCT07370532 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether adding —an anti-inflammatory medication—to your regular Parkinson's treatment can help reduce harmful brain inflammation and improve your symptoms. Researchers believe that inflammation plays an important role in Parkinson's disease, and this medication may help address that underlying problem. You would take this treatment alongside your regular Parkinson's medication for six months.
Current Parkinson's treatments help with movement symptoms, but they don't address the brain inflammation that seems to drive the disease. This medication may fill that gap by reducing inflammation while you continue your standard care.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: either continuing your current Parkinson's medication alone, or taking the same medication plus once daily. The study lasts six months, during which you'll take your assigned medications as directed and likely visit the clinic for check-ups to monitor your symptoms and how well the treatment is working.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Egypt
Phase
Testing effectiveness
Sponsor
Ihab Elsayed Hassan
Enrollment target
~60 participants
Started
January 2026
Primary completion
November 2027
Age range
50 Years – 70 Years
Last updated on clinicaltrials.gov in April 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.